Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BAY 2315497 |
Synonyms | |
Therapy Description |
BAY 2315497 (PSMA-TTC) comprises an antibody targeting PSMA radiolabeled with thorium-227, which may decrease growth of PSMA-expressing tumors (Cancer Res July 1 2017 (77) (13 Supplement) 5200, PMID: 31831560). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BAY 2315497 | PSMA-TTC|BAY2315497|BAY-2315497 | PSMA Antibody 20 | BAY 2315497 (PSMA-TTC) comprises an antibody targeting PSMA radiolabeled with thorium-227, which may decrease growth of PSMA-expressing tumors (Cancer Res July 1 2017 (77) (13 Supplement) 5200, PMID: 31831560). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03724747 | Phase I | BAY 2315497 | Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Metastatic Castration Resistant Prostate Cancer | Completed | USA | GBR | FIN | 0 |